Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

79.52
+2.142.77%
Post-market: 79.520.00000.00%19:46 EDT
Volume:2.56M
Turnover:206.25M
Market Cap:3.88B
PE:-18.40
High:88.68
Open:81.30
Low:77.84
Close:77.38
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:2.86
T/O Rate:8.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-303.41
PE(LYR):-20.98

Loading ...

Baker Bros. Advisors Reports Celcuity Share Disposal Worth $317.5 Million

Reuters
·
Jul 17

Celcuity Shares Fall as Launch Delay Eclipses US Approval for Breast Cancer Drug

Reuters
·
Jul 15

Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)

TIPRANKS
·
Jul 15

Celcuity falls -12.6%

TIPRANKS
·
Jul 15

Movement Alert|Celcuity Inc Falls 22.15% in Regular Trading, FDA Approval of Core Drug Triggers Classic Sell-the-News Selloff

Market Focus
·
Jul 15

Celcuity Shares Fall 22% as Delayed Launch of New Breast Cancer Drug Overshadows First U.S. Approval

THOMSON REUTERS
·
Jul 15

Movement Alert|Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction

Market Focus
·
Jul 15

Celcuity is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 15

Celcuity, Inc. : H.c. Wainwright Raises Target Price to $155 from $145

THOMSON REUTERS
·
Jul 15

Celcuity price target raised to $177 from $160 at Citizens

TIPRANKS
·
Jul 15

U.S. Research Roundup-equinix, Goldman Sachs, Jpmorgan

Reuters
·
Jul 15

Movement Alert|Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK

Market Focus
·
Jul 15

Stocks to Watch: Pentair, Aehr Test Systems, Celcuity, Schmid Group

Dow Jones
·
Jul 15

Celcuity announces FDA approval of Revtorpyk

TIPRANKS
·
Jul 15

Celcuity Says FDA Approves Revtorpyk for Hr+/her2- Pik3ca Wild-type Metastatic Breast Cancer

Reuters
·
Jul 15

Celcuity Announces FDA Approval of Revtorpyk™ (gedatolisib) for the Treatment of Hr+/her2-, Pik3ca Wild-type Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 15

Celcuity - Anticipates Revtorpyk Commercial Launch in Late Q3 2026

THOMSON REUTERS
·
Jul 15

Movement Alert|Celcuity Inc Falls 6.75% in After-Hours Trading, Trading at $108.9

Market Focus
·
Jul 15

US FDA Approves Celcuity's Breast Cancer Drug

Reuters
·
Jul 15

FDA: Approves Gedatolisib with Fulvestrant, with or Without Palbociclib, for Hr-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 15